Total Payments
$7,409
2024 Payments
$1,084
Companies
28
Transactions
397
Medicare Patients
11,089
Medicare Billing
$624,891
Payment Breakdown by Category
Food & Beverage$6,578 (88.8%)
Education$831.22 (11.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,578 | 363 | 88.8% |
| Education | $831.22 | 34 | 11.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,002 | 55 | $0 (2024) |
| Janssen Biotech, Inc. | $828.42 | 30 | $0 (2024) |
| PFIZER INC. | $789.47 | 48 | $0 (2024) |
| Lilly USA, LLC | $707.91 | 31 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $539.36 | 20 | $0 (2024) |
| UCB, Inc. | $499.45 | 23 | $0 (2024) |
| Amgen Inc. | $463.76 | 17 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $434.34 | 25 | $0 (2024) |
| Celgene Corporation | $416.92 | 24 | $0 (2019) |
| Genentech USA, Inc. | $238.11 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,084 | 46 | UCB, Inc. ($306.65) |
| 2023 | $1,038 | 50 | Janssen Biotech, Inc. ($255.24) |
| 2022 | $681.29 | 28 | Lilly USA, LLC ($190.42) |
| 2021 | $341.03 | 21 | AbbVie Inc. ($107.80) |
| 2020 | $287.91 | 17 | Janssen Biotech, Inc. ($127.07) |
| 2019 | $1,796 | 85 | Celgene Corporation ($319.83) |
| 2018 | $1,092 | 98 | PFIZER INC. ($263.82) |
| 2017 | $1,089 | 52 | PFIZER INC. ($274.86) |
All Payment Transactions
397 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $34.97 | General |
| Category: Immunology | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $3.95 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $16.99 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: Dermatology | ||||||
| 11/14/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: Immunology | ||||||
| 11/07/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: DERMATOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $27.44 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $13.55 | General |
| 09/25/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $30.42 | General |
| Category: Immunology | ||||||
| 09/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $4.17 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $6.96 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: IMMUNOLOGY | ||||||
| 07/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: IMMUNOLOGY | ||||||
| 07/11/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: DERMATOLOGY | ||||||
| 07/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: IMMUNOLOGY | ||||||
| 06/27/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $27.19 | General |
| Category: Immunology | ||||||
| 06/13/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $25.99 | General |
| Category: Inflammation | ||||||
| 06/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: Immunology | ||||||
| 06/06/2024 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT, ZEPBOUND | Food and Beverage | In-kind items and services | $27.47 | General |
| Category: Immunology | ||||||
| 06/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $6.18 | General |
| Category: Immunology | ||||||
| 05/11/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 983 | 1,430 | $141,773 | $54,142 |
| 2022 | 13 | 1,628 | 2,388 | $225,400 | $92,392 |
| 2021 | 15 | 3,808 | 6,016 | $544,609 | $218,485 |
| 2020 | 16 | 4,670 | 7,839 | $683,353 | $259,873 |
Total Patients
11,089
Total Services
17,673
Medicare Billing
$624,891
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 279 | 304 | $35,274 | $17,554 | 49.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 167 | 167 | $25,028 | $11,619 | 46.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 198 | 211 | $25,320 | $9,124 | 36.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 72 | 73 | $18,615 | $5,158 | 27.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 150 | 538 | $16,140 | $2,514 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 27 | $4,035 | $2,393 | 59.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 38 | 43 | $2,608 | $1,593 | 61.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 27 | 40 | $8,200 | $1,524 | 18.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $2,983 | $1,414 | 47.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 14 | 14 | $3,570 | $1,249 | 35.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 538 | 583 | $63,507 | $34,112 | 53.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 306 | 334 | $40,080 | $14,552 | 36.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 190 | 190 | $28,475 | $13,803 | 48.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 98 | 103 | $26,265 | $7,596 | 28.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 108 | 120 | $7,278 | $4,621 | 63.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 229 | 887 | $26,610 | $3,906 | 14.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 40 | 41 | $6,127 | $3,775 | 61.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $5,047 | $2,726 | 54.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 26 | 26 | $6,630 | $2,506 | 37.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 14 | 14 | $3,466 | $1,878 | 54.2% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 26 | 34 | $6,970 | $1,308 | 18.8% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 20 | 20 | $2,073 | $958.66 | 46.2% |
| 11105 | Punch biopsy, each additional skin growth | Office | 2022 | 11 | 14 | $2,870 | $650.66 | 22.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 1,320 | 1,551 | $159,918 | $88,056 | 55.1% |
| 17000 | Destruction of skin growth | Office | 2021 | 760 | 885 | $106,200 | $36,795 | 34.6% |
About Dr. William Jaremko, M.D
Dr. William Jaremko, M.D is a Dermatology healthcare provider based in Olean, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1417941733.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Jaremko, M.D has received a total of $7,409 in payments from pharmaceutical and medical device companies, with $1,084 received in 2024. These payments were reported across 397 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($6,578).
As a Medicare-enrolled provider, Jaremko has provided services to 11,089 Medicare beneficiaries, totaling 17,673 services with total Medicare billing of $624,891. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Olean, NY
- Active Since 09/01/2005
- Last Updated 01/06/2026
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1417941733
Products in Payments
- EUCRISA (Drug) $745.51
- TALTZ (Drug) $588.53
- TREMFYA (Drug) $588.26
- Otezla (Drug) $577.59
- SKYRIZI (Biological) $446.76
- Bimzelx (Biological) $331.59
- ILUMYA (Biological) $286.27
- COSENTYX (Biological) $272.21
- Humira (Biological) $241.53
- Erivedge (Biological) $238.11
- DUPIXENT (Drug) $198.86
- Tremfya (Drug) $197.17
- Cimzia (Drug) $167.86
- Enbrel (Biological) $165.59
- SILIQ (Drug) $133.14
- COSENTYX (Drug) $119.04
- DUPIXENT (Biological) $101.24
- VTAMA (Drug) $98.00
- RINVOQ (Biological) $93.28
- OPZELURA (Drug) $83.71
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.